Drs Robert Glatter and Amy Faith Ho continue their review of The Pitt season 2, tackling retinal artery occlusion, phytophotodermatitis, and ovarian torsion. They unpack clinical accuracy, informed consent, and bias in emergency care. Medscape Emerg…
Category: News
Asset Value Investors (AVI)呼籲Rohto Pharmaceutical專注核心業務，並與股東進行更具建設性的溝通
倫敦–(BUSINESS WIRE)–(美國商業資訊)– Asset Value Investors Limited (「AVI」)今日宣布，就其針對Rohto Pharmaceutical Co., Ltd. (TSE：4527，「Rohto」)的公開倡議發佈最新進展。此行動為去年發起、旨在提升該公司企業價值的持續性倡議「Awakening Rohto」之後續。AVI已在專屬網站(www.AwakeningRohto.com)上發布了詳細的簡報。 自2024年6月開始投資以來，AVI一直試圖…
Bruno Vision Care Wins 2026 MedTech Breakthrough Award
BOCA RATON, Fla.–(BUSINESS WIRE)– #ContactLenses–Bruno Vision Care’s FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award.
CGRP Inhibitors for Migraine Linked to Reduced Glaucoma Risk
The use of calcitonin gene-related peptide (CGRP) inhibitors to treat adults with migraine is linked to a 25% lower risk for glaucoma than the use of non-CGRP inhibitors, a new study shows. Medscape Medical News
Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders
LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (“AVI”) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, “Rohto”), as a follow-up to its ongoing campaign, “Awakening Rohto”, launched last year…
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy…
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026
ALBANY, N.Y. & SHANGHAI–(BUSINESS WIRE)–Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented at the Association for Research in …
Certain Multiple Sclerosis Drugs Tied to Lower Uveitis Risk
The use of nucleic acid synthesis inhibitors or sphingosine-1-phosphate modulators, fumarates, or interferons is linked to a lower risk for noninfectious uveitis in patients with MS, a new study finds. Medscape Medical News
Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #ASGCT–Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today a…
New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
GENEVA–(BUSINESS WIRE)–New Product Launches Drive Alcon’s First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
GENEVA–(BUSINESS WIRE)–New Product Launches Drive Alcon’s First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has …
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership
SAN FRANCISCO & COLUMBUS, Ohio–(BUSINESS WIRE)–Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto…
BlinkRx Announces Availability of RYALTRIS® for Convenient Home Delivery Following Glenmark’s Commercial Transition
NEW YORK–(BUSINESS WIRE)–RYALTRIS® nasal spray for seasonal allergic rhinitis is now available through BlinkRx. Transfer your Rx or visit blinkrx.com to learn more.
Viridian Eye Disease Drug Surpasses Expectations in Late-stage Trial; Shares Soar
Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients, sending its shares up nearly… Reuters Health Information
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent bus…
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive …
Samenvatting: Kubota Vision Inc. sluit een leverings- en licentieovereenkomst met Laboratoires KÔL voor een kandidaat-geneesmiddel tegen de ziekte van Stargardt in het kader van de schrijnende gevallenregeling
CLERMONT-FERRAND, Frankrijk & TOKIO, Japan–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), een volledige dochteronderneming van Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokio, Japan), heeft bekendgemaakt dat het een leverings- en li…
Riassunto: Kubota Vision Inc. firma un accordo di fornitura e licenza con Laboratoires KÔL per un farmaco ad uso compassionevole candidato al trattamento della malattia di Stargardt
CLERMONT-FERRAND, Francia e TOKYO, Giappone–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), azienda interamente controllata da Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Giappone) ha annunciato la firma di un accordo di fornitu…
Kubota Vision Inc. unterzeichnet Liefer- und Lizenzvereinbarung mit Laboratoires KÔL über einen Wirkstoffkandidaten zur Behandlung der Stargardt-Krankheit im Rahmen einer Compassionate-Use-Behandlung
CLERMONT-FERRAND, Frankreich & TOKIO, Japan–(BUSINESS WIRE)–Kubota Vision Inc. („Kubota Vision“), eine hundertprozentige Tochtergesellschaft der Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokio, Japan), gab die Unterzeichnung eines Liefer- …